A cross-sectional study of α-synuclein seed amplification assay in Alzheimer's disease neuroimaging initiative: Prevalence and associations with Alzheimer's disease biomarkers and cognitive function.
Duygu TosunZachary HausleHirotaka IwakiPamela ThroppJennifer LamoureuxEdward B LeeKaren MacLeodSean McEvoyMichael NallsRichard J PerrinAndrew J SaykinLeslie M ShawAndrew B SingletonRuss LebovitzMichael W WeinerCornelis Blauwendraatnull nullPublished in: Alzheimer's & dementia : the journal of the Alzheimer's Association (2024)
SAA shows 79% sensitivity, 97% specificity for LB-pathology detection in AD. SAA positivity prevalence increases with disease stage and age. Higher Aβ burden, lower CSF p-tau181 linked with higher SAA+ rates in dementia. SAA+ impacts cognitive impairment in early disease stages. Study underpins need for wider LB-pathology screening in AD treatment.